This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

When to retest vitamin D levels in the management of vitamin D deficiency in an adult

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • it is recommended to re-check vitamin D levels 6 months after a course of high dose vitamin D replacement

    • if levels are still sub-optimal, compliance with medication should be discussed with the patient, then treatment repeated. Re-testing should not be done sooner than 6 months after starting treatment, as it can take 6 months to reach steady state on treatment

    • treatment with high dose vitamin D is unlikely to lead to toxicity. If concerned, serum calcium levels are a more appropriate indicator of toxic levels of vitamin D.

Notes:

  • salcium and vitamin D combined supplements are not routinely indicated in patients with low vitamin D3 levels unless the patient also has hypocalcaemia. The calcium component may be unnecessary and can reduce compliance due to unpalatability. Serum calcium levels should, however, be monitored
  • short acting potent analogues of vitamin D such as alfacalcidol or calcitriol should NOT be used in the management of vitamin D deficiency in adults because there is no evidence to support efficacy and it can lead to hypercalcaemia

Reference:

  • 1) NHS Coventry and Warwickshire. Brief Prescribing guide - Treatment of Vitamin D Deficiency in Adults (February 2012)

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.